SELLAS (NASDAQ: SLS) Cancer Vaccine Cuts Death Risk 41% in Pivotal AML Trial - Stock Soars with Triple Digit Gains

SELLAS Life Sciences (NASDAQ: SLS) reported positive results from its Phase 3 REGAL trial, showing a 41% reduction in death risk for AML patients using its cancer vaccine, galinpepimut-S. The stock surged 170.42% to $20.20 on high volume. SELLAS plans to discuss accelerated FDA filing for the vaccine in 2027.

Original reporting
Published Nov 17, 2026, 4:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 7:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SELLAS (NASDAQ: SLS) Cancer Vaccine Cuts Death Risk 41% in Pivotal AML Trial - Stock Soars with Triple Digit Gains — source image
Decision brief

The 30-second read

$SLSBullishHigh
01

Why it matters

The disclosed hazard ratio, p-value, and median OS comparison represent a material clinical milestone, and the stated plan to discuss accelerated filing with the FDA and prepare a BLA for H1 2027 creates a concrete near-to-medium term catalyst path.

02

Market read

Traders have a fresh, company-specific catalyst: pivotal OS-positive Phase 3 topline results and an accelerated regulatory filing timeline, supporting immediate repricing and watch for follow-on conference/publication details.

03

What to watch

The article does not provide details on secondary endpoints, durability beyond median OS, or manufacturing/CMC readiness for accelerated filing, which can temper follow-through.

Relevance 9/10Novelty 9/10Timing: same-day catalyst, pre-market/market-open reaction to Phase 3 topline results

Background

SELLAS is a late-stage biopharmaceutical company developing WT1-targeted immunotherapies; REGAL is a pivotal Phase 3 trial in AML patients in second remission who are ineligible for or unable to undergo allogeneic stem cell transplantation.

Company-level read

Ticker impact

$SLSBullishHigh confidence
Context

SELLAS reported positive topline Phase 3 REGAL results for galinpepimut-S in AML, meeting the OS primary endpoint with a 41% death-risk reduction vs BAT.

Expected impact

Likely further upside pressure as traders price in accelerated BLA timing and the magnitude of the OS benefit.

Evidence & confidence

The article discloses statistically significant OS improvement (HR 0.59, p=0.035), favorable safety, and a stated intent to pursue accelerated filing with BLA preparations for H1 2027.

Market effects

Reinforces investor appetite for late-stage immunotherapy and WT1-targeted vaccine platforms in AML maintenance settings.

Primarily US biotech sentiment, with potential spillover to other AML-focused names on trial-readthrough expectations.

Limited direct global macro linkage; mainly affects global biotech risk appetite for AML immunotherapies.

Counterpoint

Topline OS results may face volatility as investors wait for full secondary endpoint details, subgroup analyses, and FDA feedback on the accelerated pathway.

Key entities

  • SELLAS Life Sciences Group, Inc.

    Sponsor of the pivotal Phase 3 REGAL trial evaluating galinpepimut-S (GPS) in AML maintenance therapy.

  • galinpepimut-S (GPS)

    WT1-targeted immunotherapeutic cancer vaccine evaluated as maintenance monotherapy in REGAL.

  • REGAL trial

    Pivotal randomized Phase 3 study in AML second remission patients comparing GPS vs investigator’s choice of best available treatment.

  • U.S. Food and Drug Administration (FDA)

    Regulatory authority SELLAS plans to engage with regarding an accelerated filing strategy and BLA preparations.

Related articles

$NVDAMedAI 8/10

Futures Rise As Huang-less Nvidia Beats And Raises, Gold Crashes Below $3,800

US futures rise as Nvidia (NVDA) reports strong earnings and raises guidance, boosting AI-related stocks. Gold drops below $3,800 after Fed Governor Waller's comments. Nvidia's Q4 revenue guidance is $130B vs. estimates of $125B. Premarket movers include TSLA, GOOGL, AMZN, AAPL, META, AVGO, CRWV, AAOI, BLSH, DLB, LOW, SLS, TTWO, TNDM. Fed policy and economic data releases are in focus.

$SLSHighAI 9/10

SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From Here

Sellas Life Sciences (SLS) reported positive Phase 3 trial results for its cancer vaccine, Galinpepimut-S (GPS), showing a 24-month median survival vs. 14.7 months in the control group. The company plans to meet with the FDA and aims to file for approval in early 2027. SLS also announced a $150M share offering to fund further development. Analysts and investors reacted positively, with some noting potential for expedited approval and broader applications.

$SLSHighAI 9/10

SLS Joins MRNA And ANL In Biotech’s Top 3 Winners This Year — Can Sellas Deliver Another Double From Here?

Sellas Life Sciences (SLS) stock surged 156% to $19.15 after positive Phase 3 trial results for its leukemia vaccine, Galinpepimut-S. The trial showed a 41% reduction in death risk, with median survival of 24 months vs. 14.7 months in the control group. Maxim Group raised its price target to $40, citing significant upside potential. SLS is planning a $150M share offering to fund further development.

$SLSMedAI 8/10

SELLAS shares jump 157% after company says its leukemia

SELLAS Life Sciences (SLS) shares surged 157% after reporting positive Phase 3 trial results for its leukemia vaccine, galinpepimut-S, showing a 41% reduction in death risk. The stock closed at $19.17, valuing the company at $3.9B. However, after launching a $150M stock offering, shares dropped 10-13% in after-hours trading. The trial enrolled 126 patients, with median survival of 24.0 months vs. 14.7 months for existing treatments. The company plans to file for regulatory approval in 2027.